Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Insulin efsitora alfa - Eli Lilly and Company

Drug Profile

Insulin efsitora alfa - Eli Lilly and Company

Alternative Names: Basal Insulin-FC - Eli Lilly and Company; LY-3209590

Latest Information Update: 19 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd
  • Class Antihyperglycaemics; Immunoglobulin Fc fragments; Insulins; Pancreatic hormones; Recombinant fusion proteins
  • Mechanism of Action Insulin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 07 Dec 2023 Phase-I clinical trials in Type 2 diabetes mellitus in Germany (SC) (NCT06169982)
  • 06 Dec 2023 Eli Lilly and Company plans a phase I trial for Type 2 diabetes mellitus (Treatment-naïve) in Germany (SC) (NCT06169982) (EudraCT2023-508008-39-00) in December 2023
  • 10 Oct 2023 Eli Lilly and Company completes a phase I trial in Type 2 Diabetes mellitus (In Adults, In Elderly) (SC) in China (NCT05596747)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top